View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter’s Weekly Newsletter
John Kastelein is a renowned expert in lipoprotein metabolism and atherosclerotic cardiovascular disease (ASCVD) research. In this discussion, John delves deep into familial hypercholesterolemia (FH), a genetic disorder characterized by high levels of LDL cholesterol in the blood that increases the risk of developing heart disease. He covers its definition, genetic underpinnings, and clinical identification. He then explores the therapeutic options available for the prevention and treatment of cardiovascular disease, including the captivating history of CETP inhibitors. He explains the past shortcomings of previous CETP inhibitors before underscoring the compelling potential of the latest iterations, not only for cardiovascular disease but also for conditions like Alzheimer's disease and type 2 diabetes. Moreover, he unveils the intricate role of APOE, shedding light on why the APOE4 isoform codes for a protein that significantly increases the risk of Alzheimer's disease and cardiovascular disease. Concluding the discussion, John shares a profound sense of optimism, envisioning the possibility of targeted therapeutic interventions for high-risk patients in the near future.
We discuss:
Connect With Peter on Twitter, Instagram, Facebook and YouTube
#157 - AMA #22: Losing fat and gaining fat: the lessons of fat flux
#156 - Jake Muise: Humanely harvesting axis deer while alleviating its impact on Hawaii’s vulnerable ecosystems
#155 - Chris Sonnenday, M.D.: The history, challenges, and gift of organ transplantation
#154 - Steve Levitt, Ph.D.: A rogue economist’s view on climate change, mental health, the ethics of experiments, and more
#153 - AMA #21: Deep dive into olive oil, high-intensity exercise, book update, and more
#152 - Michael Rintala, D.C.: Principles of Dynamic Neuromuscular Stabilization (DNS)
#151 - Alex Hutchinson, Ph.D.: Translating the science of endurance and extreme human performance
#150 - Senator Bill Frist, M.D.: A modern Renaissance man's journey through science, politics, and business
#149 - AMA #20: Simplifying the complexities of insulin resistance: how it's measured, how it manifests in the muscle and liver, and what we can do about it
#148 - Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the Interventions Testing Program
#147 - Hussein Yassine, M.D.: Deep dive into the “Alzheimer’s gene” (APOE), brain health, and omega-3s
#146 - Guy Winch, Ph.D.: Emotional first aid and how to treat psychological injuries
#145 - AMA #19: Deep dive on Zone 2 training, magnesium supplementation, and how to engage with your doctor
#144 - Phil Maffetone: Optimizing health and performance through maximal aerobic function
#143 - John Ioannidis, M.D., D.Sc.: Why most biomedical research is flawed, and how to improve it
#142 - Robert Abbott: The Bobby Knight story—a cautionary tale of unchecked anger, ego, and winning at all costs
#141 - AMA #18: Deep dive: sugar and sugar substitutes
#140 - Gerald Shulman, M.D., Ph.D.: A masterclass on insulin resistance—molecular mechanisms and clinical implications
#139 - Kristin Neff, Ph.D.: The power of self-compassion
#138 - Lauren Miller Rogen and Richard Isaacson, M.D.: Alzheimer’s disease prevention—patient and doctor perspectives
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Huberman Lab
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.